Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (7613)	5/4/1998 2:04:00 AM
From: N/E PATSFAN	Read Replies (1) \| Respond to of 9262

[ Chat ] Hey Ray! Sorry I haven't responded to your post..." north east " ... but just getting caught up after extended breather. Couldn't take all that fast action with the internets and got especially disappointed with action in APLX after only meeting earnings expectations...regrets to Rainier and his thread for my post...I thought I had a good "short term" play but "humble pie is served". Regards, NEPF P.S. Congrats to CW on ALMI and you on HCOM !!

To: Galirayo who wrote (7613)	5/4/1998 2:24:00 AM
From: John Metcalf	Read Replies (2) \| Respond to of 9262

Rick Harmon had an article on angiogenesis on Microsoft Investor. It doesn't seem to be available anymore. The companies named in the article were SUGN, GNE, IMCL, SCIO, REGN, RGEN, AGPH, and ENMD. SUGN is probably the best bet for a sympathy move with ENMD. ENMD might be favored for longer horizons, because of its partnership with BMY, and because Dr. Folkman is a leader in angiogenesis. I don't know the status of the VGEF program at Agouron. Hopefully, Rick will have something to add -- he has published on the subject.